Cinnamon

drug
On this page

Also known as Ae-cinnamonB1472Ceylon cinnamonCeylon cinnamon barkCinnamomi ceylanici cortexCinnamomumCinnamomum s wholeCinnamomum verumCinnamomum verum barkCinnamomum verum inner barkCinnamomum verum powderCinnamomum verum stem barkCinnamomum verum wholeCinnamomum zeylanicum barkCinnamomum zeylanicum bark powderCinnamomum zeylanicum inner barkCinnamon (cinnamomum zeylanicum)Cinnamon barkCinnamon ceylon

Summary

Cinnamon (CHEMBL2108924) is a phase-3 clinical-stage unknown; indicated across 6 conditions including polycystic ovary syndrome and diabetes mellitus.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Indications: 6 conditions
  • Clinical trials: 34

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108924
NameCinnamon
TypeUnknown
Max phase3

Also known as: Ae-cinnamon, B1472, Ceylon cinnamon, Ceylon cinnamon bark, Cinnamomi ceylanici cortex, Cinnamomum, Cinnamomum s whole, Cinnamomum verum, Cinnamomum verum bark, Cinnamomum verum inner bark, Cinnamomum verum powder, Cinnamomum verum stem bark

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
polycystic ovary syndrome3MONDO:0008487EFO:0000660
diabetes mellitus3MONDO:0005015EFO:0000400
dental caries3MONDO:0005276EFO:0003819
obesity disorder2MONDO:0011122EFO:0001073
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
type 2 diabetes mellitus2MONDO:0005148MONDO:0005148

Clinical trials

Total trials: 34.

Phase distribution

PhaseTrials
Not specified18
PHASE34
PHASE24
PHASE2/PHASE32
PHASE12
EARLY_PHASE12
PHASE41
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07518394PHASE4COMPLETEDOral Essential Oils Efficacy in Acute Respiratory Symptoms
NCT00371800PHASE2/PHASE3COMPLETEDThe Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes
NCT00445354PHASE3COMPLETEDRandomized Controlled Clinical Trial of Cinnamon to Lower Hemoglobin A1c
NCT01483118PHASE3COMPLETEDCinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)
NCT03061916PHASE3UNKNOWNCinnamon and Ginger in Comparison to Chlorhexidine Gluconate 0.2% on Oral Streptococcus Mutans
NCT03610412PHASE3COMPLETEDCinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated
NCT03711682PHASE2/PHASE3COMPLETEDReducing Plasma Glucose Effect of Cinnamon in Type 2 Diabetic Patients in the Municipality of Comasagua
NCT00846898PHASE2COMPLETEDIs There a Metabolic Effect of Cinnamon on HbA1c, Blood Pressure and Serum Lipids in Type 2 Diabetes Mellitus?
NCT01847053PHASE1/PHASE2COMPLETEDBioavailability Study of Cinnamon in Healthy Subjects
NCT02942056PHASE2WITHDRAWNThe Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus
NCT03219411PHASE2COMPLETEDEffects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes
NCT04846231PHASE2COMPLETEDSupplements, Placebo, or Rosuvastatin Study
NCT00331279PHASE1COMPLETEDThe Effect of Cinnamon Extract on Insulin Resistance Parameters in Polycystic Ovary Syndrome: A Pilot Study
NCT00970541PHASE1TERMINATEDEffect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome
NCT03946163EARLY_PHASE1COMPLETEDThe Effect of Cinnamon on Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome; a Pilot Study
NCT05157672EARLY_PHASE1UNKNOWNEvaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon
NCT05685628Not specifiedRECRUITINGEvaluation of the Quality of Life Induced by the Cinnamon Anti-odor Dressing in Patients With Malodorous Wounds
NCT06286735Not specifiedACTIVE_NOT_RECRUITINGEffects of Cinnamomum Supplementation in Chronic Kidney Disease Patients
NCT00951639Not specifiedCOMPLETEDCassia Cinnamon for Glucose Uptake in Young Women
NCT01085019Not specifiedCOMPLETEDImpact of Spices and Herbs on Endothelial Function
NCT01350284Not specifiedCOMPLETEDThe Effect of Natural Food Flavourings on Gastrointestinal and Cardiovascular Physiological Responses.
NCT02404701Not specifiedCOMPLETEDEffect of Over-the-counter Dietary Supplements on Kidney Stone Risk
NCT02422576Not specifiedCOMPLETEDEfficacy of Natural Ingredient to Improve the Swallowing Response of Patients With Oropharyngeal Dysphagia
NCT02455778Not specifiedCOMPLETEDEffect of Oral Cinnamon Intervention in Metabolic Syndrome
NCT03926442Not specifiedCOMPLETEDSpices, Inflammation and Vascular Response in Humans
NCT04023539Not specifiedCOMPLETEDEffect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
NCT04259606Not specifiedUNKNOWNEffect of Cassia Cinnamon on Arterial Stiffness Parameters in Patients With Type 2 Diabetes Mellitus
NCT04342624Not specifiedCOMPLETEDInvestigation of Cinnamon Spice on Glucose Tolerance in Subjects With Pre-diabetes
NCT04476160Not specifiedCOMPLETEDEffectiveness of Cinnamon on Insulin Resistance ( ECIRCCOS ) December 1, 2019
NCT04686552Not specifiedCOMPLETEDEffect Cinnamon Spice on Postprandial Glucose and Insulin Responses
NCT06119555Not specifiedUNKNOWNEffect of Cinnamon Powder Capsules on Body Composition
NCT06199024Not specifiedUNKNOWNCinnamon and COH in PCOS Women Underdoing IVF/ICSI Cycles
NCT06423248Not specifiedCOMPLETEDCulinary Spices in Metabolic Syndrome.
NCT06976255Not specifiedCOMPLETEDThe Effect of Dark Chocolate and Cinnamon Sugars on Pain and Anxiety in University Students With Primary Dysmenorrhea

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).